spacer
home > epc > winter 2018 > ticking boxes
PUBLICATIONS
European Pharmaceutical Contractor

Ticking Boxes

With the advent of novel immuno-therapeutic approaches to cancer, the world has entered a new stage of medicine. Rather than targeting cancer cells directly with traditional tools like chemotherapy or radiation, immunotherapy seeks ways to use the bodyís own immune system to eradicate or inhibit the growth of cancers.

The field of immuno-oncology (IO) focuses on determining how to activate pre-existing immune cells to attack cancerous targets. Monoclonal antibody therapies have shown to be successful in many indications and continue to be an effective and viable approach to treating cancer. According to Beth Kiernan, pharmaceutical research analyst at Thomson Reuters, therapeutic cancer vaccines currently comprise 14% of IO clinical trials (1). Although many vaccine trials are in early stages, advancement has been made into later stages, showing potential for desirable outcomes using this strategy.

Perhaps the most groundbreaking and rapidly expanding modality of IO is the development of the utilisation of checkpoint inhibitors. Though the industry is just scratching the surface of its promise, checkpoint inhibitors have profound implications on the future of oncological therapies, revolutionising the research industry. Checkpoint inhibitor therapies are able to span across cancer types and stages, providing hope even in the most despairing of circumstances.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Elizabeth Koury is Vice President of Scientific Affairs at LabConnect. She is responsible for leading a team of scientists, sample management professionals, and contract managers strategically supporting clients within the pharma industry. Elizabeth earned a bachelorís in biology/allied health from Elizabethtown College, US, and a masterís in pharmaceutical chemistry from Lehigh University, US. She has more than 20 years of experience in conducting and overseeing scientific research in the areas of neuroscience, oncology, and immunology.

Jeff Mayhew is Chief Development Officer at LabConnect. As one of the founding partners in 2002, he has three decades of operations and business development experience within the healthcare industry. Before starting LabConnect, Jeff was founder and Director of Nexus Health Management International, where he was involved in the development of inpatient behavioural health services in Southeast Asia. Prior to that, he served as Vice President of Strategic Alliance Development for Charter Behavioural Health Systems, among other key leadership positions.
spacer
Elizabeth Koury
spacer
spacer
spacer
Jeff Mayhew
spacer
spacer
Print this page
Send to a friend
Privacy statement

White Papers

Considerations for Choosing the Right Wearable Drug Delivery System

West Pharmaceutical Services, Inc.

For patients with chronic conditions, the use of injectable biologic therapies is on the rise. Biologics, while providing considerable therapeutic benefit, can also present several challenges for both drug manufacturers and patients. In particular, many biologics are highly viscous and others require large doses to be injected slowly over time. This can make it difficult to deliver a consistent dose every time, potentially impacting medication adherence.
More info >>

 
Industry Events

PDA Parenteral Packaging 2019

19-20 March 2019, Hilton Molino Stucky, Venice, Italy

PDA Europeís Conference has become a must-attend event for all professionals in the Parenteral Packaging arena. Join us in Venice in March 2019 to continue and further deepen scientific advancements and our ongoing professional discourse of latest on primary packaging technologies and business trends. This conference and the accompanying exhibition address quality of components and cont≠ainers, container closure development and integrity testing as well as aspects of processing, product distribution and storage.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement